FMR1NB | Fragile X mental retardation 1 neighbor | Predicted membrane proteins
| | | | | Tissue enriched |
MAGEC1 | Melanoma antigen family C, 1 | Cancer-related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
SPINK2 | Serine peptidase inhibitor, Kazal type 2 (acrosin-trypsin inhibitor) | Predicted secreted proteins
| | | | | Tissue enriched |
ELAVL2 | ELAV like neuron-specific RNA binding protein 2 | Predicted intracellular proteins
| | | | | Group enriched |
CXorf67 | Chromosome X open reading frame 67 | Predicted intracellular proteins
| | | | | Group enriched |
PNMA5 | Paraneoplastic Ma antigen family member 5 | Predicted intracellular proteins
| | | | | Group enriched |
IGF2BP1 | Insulin-like growth factor 2 mRNA binding protein 1 | Predicted intracellular proteins
| | | | | Group enriched |
ATP6V1E2 | ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E2 | Predicted intracellular proteins
| | | | | Tissue enriched |
DCUN1D1 | DCN1, defective in cullin neddylation 1, domain containing 1 | Predicted intracellular proteins
| | | | | Tissue enriched |
CTAG1A | Cancer/testis antigen 1A | Cancer-related genes Predicted intracellular proteins
| | | | | Tissue enriched |
KHDRBS3 | KH domain containing, RNA binding, signal transduction associated 3 | Predicted intracellular proteins
| | | | | Group enriched |
MRGBP | MRG/MORF4L binding protein | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
STAG3 | Stromal antigen 3 | Disease related genes Predicted intracellular proteins
| | | | | Tissue enriched |
BAG5 | BCL2-associated athanogene 5 | Predicted intracellular proteins
| | | | | Tissue enriched |
LYAR | Ly1 antibody reactive | Predicted intracellular proteins Transcription factors
| | | | | Tissue enriched |
TCFL5 | Transcription factor-like 5 (basic helix-loop-helix) | Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
ARID3B | AT rich interactive domain 3B (BRIGHT-like) | Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
CASC5 | Cancer susceptibility candidate 5 | Cancer-related genes Disease related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
CDC25C | Cell division cycle 25C | Cancer-related genes Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
CNTRL | Centriolin | Cancer-related genes Disease related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
DIAPH3 | Diaphanous-related formin 3 | Cancer-related genes Disease related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
HMMR | Hyaluronan-mediated motility receptor (RHAMM) | CD markers FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
ISYNA1 | Inositol-3-phosphate synthase 1 | Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
KIF2C | Kinesin family member 2C | Cancer-related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
NANOG | Nanog homeobox | Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
SGOL2 | Shugoshin-like 2 (S. pombe) | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
TOP2A | Topoisomerase (DNA) II alpha 170kDa | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
TTBK2 | Tau tubulin kinase 2 | Disease related genes Enzymes Potential drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
VRTN | Vertebrae development associated | Predicted intracellular proteins
| | | | | Tissue enhanced |